Cancer/Tumor Profiling Market by Technique (genomics, proteomics, metabolomics, and epigenomics), by Technology (Immunoassay, NGS, Insitu Hybridization, Mass, Spectrometry, PCR, Microarray and Others) and by Application (Research Application and Clinical Application)- Global Opportunity Analysis and Industry Forecast 2022-2030

Cancer/Tumor Profiling Market

Industry:  Life Sciences & Healthcare | Publish Date: Mar 2022 | No of Pages:  592 | No. Tables:  760 | No. Figures:  387

Market Definition:

The Cancer/Tumor Profiling Market size was valued at USD 11.10 billion in 2021 and is predicted to reach USD 31.67 billion by 2030 with a CAGR of 11.8% from 2022-2030.

Cancer profiling or the tumor profiling is a laboratory test conducted to identify certain genes or the gene mutations, proteins, or other biomarkers in a sample of tumor tissue. Tumor profiling can aid in treatment planning and predicting if cancer will return or spread to other places of the body.

Cancer profiling is not only effective in the molecular profiling of common malignancies like lymphoma and breast cancer, but also in the molecular profiling of lung cancer, prostate cancer, and acute leukaemia. Cancer profiling has become more important in molecular diagnosis, since a better knowledge of cancer tumor allows clinicians to make more informed therapeutic decisions and prevent "over-treating" cancer patients.

Market Dynamics and Trends:

Growing prevalence of cancer globally and increasing adoption of precision medicine options are pacing new paths for the advanced diagnostic products for determination of the cancerous gene and targeted therapies for the identical.

According to the International Agency for Research on Cancer, 1 in 5 people develop cancer during their lifetime across globe. Also, 1 in 8 men and 1 in 11 women die from the disease indicating significant need for effective diagnostic and therapeutic options. In addition, increasing new cancer cases owing to ageing population and lifestyle changes are likely to drive the demand for cancer profiling products in the coming years.

Moreover, new estimates from GLOBOCAN suggests that quite 50 million people live within five years of past cancer diagnosis. Factors such as increased research and development activities and new product approvals are expected to enhance the market growth.

Furthermore, enormous sums of money are raised for the development of cancer-fighting products. According to a study published by ecancer-medicalscience, roughly 153 public research funding organizations (RFO) in the EU and the United States spent more than €1 million on oncology each year. RFOs in the EU spent a total of €2.79 billion, while RFOs in the US spent a total of €5.8 billion.

However, the high cost of cancer profiling tests, as well as a lack of access to the healthcare infrastructure required for cancer profiling, are limiting the market's expansion over the forecast period. Tumor profiling tests are cutting-edge, and they function by identifying tumor mutations and establishing a therapy pathway tailored to the patient's needs. Due to the exorbitant cost of these tests, which are such a sophisticated technology, they are only used by a small percentage of the population in economically depressed areas.

Other factors affecting market growth in the AMEA include a lack of understanding about sophisticated technology, low spending capacity, lack of access to healthcare facilities, and cancer detection at a later stage.

 

Market Segmentations and Scope of the Study:

The Cancer Tumor Profiling market is segmented on the basis of technique, technology, application and geography. On the basis of technique, the market is divided into genomics, proteomics, metabolomics, and epigenomics. On the basis of technology, the market is classified into immunoassay, NGS, insitu hybridization, mass spectrometry, pcr, microarray and others. On the basis of insitu hybridization, the market is further sub segmented into FISH and CISH. On the basis of application, the market is categorized into research applications and clinical applications. On the basis of research applications, the market is further sub segmented into biomarker discovery and personalized cancer medicine. On the basis of clinical application, the market is further classified into oncological diagnostics, prognostics, monitoring and treatment, screening. Geographic breakdown and analysis of each of the aforesaid segments includes regions comprising of North America, Europe, Asia-Pacific, and RoW.

 

Geographical Analysis:

North America region is anticipated to hold the highest market share during the forecast period. This is due to the factors such as growing new product launches in countries like the United States and Canada, and increasing prevalence of patients suffering from cancer, advancements in technologies, and high consumer awareness. With a high number of companies active in cancer research and targeted drug delivery development, oncology biomarker testing is becoming more popular in the region.

Furthermore, the high cost of products in the United States, as well as the growing number of genome sequencing program, make it an appealing market. The US National Cancer Institute (NCI) established the Cancer Genome Atlas program, which has sequenced more than 20,000 primary cancer samples from 33 cancer types.

However, the cancer profiling market, on the other hand, is predicted to grow at the fastest rate in Asia Pacific. This is due to an increase in cancer cases in the area. Countries like India, China, and South Korea are demonstrating remarkable economic growth and, as a result, improved healthcare infrastructure, which in turn is also drives the growth of the market in this region.

 

Competitive Landscape:

The Cancer Tumor Profiling market comprising of various market players such as Lucence Health Inc., F. Hoffmann-La Roche Ltd, Caris Life Sciences, ACT Genomics Co., LTD, Thermo Fisher Scientific Inc., Strand Life Sciences, IMB Dx, Inc., Illumina, Inc., Guardant Health, QIAGEN, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics, Inc., NanoString, NeoGenomics Laboratories and Exact Sciences Corporation (Genomic Health, Inc.). These market players are adopting various joint venture strategies and planning expansion of business across various regions to maintain their dominance in the cancer tumor profiling market.

For instance, in November 2021, Lucence in partnership with VA Palo Alto Healthcare System launched liquid biopsy screening study. The study examines the utilization of non-invasive liquid biopsy for high-risk patients together with imaging tools for lung cancer screening.

Also, in October 2021, Roche in collaboration with PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology developed an embedded image analysis workflow for pathologists. This can benefit cancer patients through more precise diagnosis, there by leading to targeted treatment.

KEY BENEFITS:

  • The cancer tumor profiling market report provides the quantitative analysis of the current market and estimations through 2021-2030 that assists in identifying the prevailing market opportunities to capitalize on.

  • The study comprises a deep dive analysis of the cancer tumor profiling market trend including the current and future trends for depicting the prevalent investment pockets in the market.

  • The information related to key drivers, restraints and opportunities and their impact on the cancer tumor profiling market is provided in the report.

  • The competitive analysis of the market players along with their market share in the cancer tumor profiling market

  • The SWOT analysis and Porters Five Forces model is elaborated in the study.

  • Value chain analysis in the market study provides a clear picture of the stakeholders’ roles.

KEY MARKET SEGMENTS:

By Technique

  • Genomics

  • Proteomics

  • Metabolomics

  • Epigenomics

By Technology

  • Immunoassay

  • NGS

  • Insitu Hybridization

    • FISH

    • CISH

  • Mass Spectrometry

  • PCR

  • Microarray

  • Others

By Application

  • Research Applications

    • Biomarker Discovery

    • Personalized Cancer Medicine

  • Clinical applications

    • Oncological Diagnostics

    • Prognostics

    • Monitoring And Treatment

    • Screening

By Geography

  • North America

    • U.S

    • Canada

  • Europe

    • Germany

    • France

    • UK

    • Spain

    • Italy

    • Rest of the Europe

  • Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Singapore

    • Australia

    • Indonesia

    • Vietnam

    • Res of the Asia Pacific

  • Latin America
    • Brazil

    • Mexico

    • Rest of LATAM

  • Middle East

    • Isreal

    • UAE

    • Saudi Arabia

    • Rest of the Middle East

  • Africa

    • South Africa

    • Nigeria

    • Rest of Africa

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Analysis Period

2020–2030

Base Year Considered

2020

Forecast Period

2021–2030

Market Size Estimation

Billion (USD)

Market Segmentation

By Technique (genomics, proteomics, metabolomics, and epigenomics), by Technology (Immunoassay, NGS, Insitu Hybridization, Mass, Spectrometry, PCR, Microarray and Others) and by Application (Research Application and Clinical Application)

Geographical Segmentation

North America (U.S., Canada) Europe (Germany, France, UK, Spain, Italy, Rest of the Europe), Asia-Pacific (China, India, Japan, South Korea, Singapore, Australia, Indonesia, Vietnam, Res of the Asia Pacific), Latin America (Brazil, Mexico, Rest of LATAM) Middle East (Isreal, UAE, Saudi Arabia, Rest of the Middle East) Africa (South Africa, Nigeria, Rest of Africa)

Companies Profiled

Lucence Health Inc., F. Hoffmann-La Roche Ltd, Caris Life Sciences, ACT Genomics Co., LTD, Thermo Fisher Scientific Inc., Strand Life Sciences, IMB Dx, Inc., Illumina, Inc., Guardant Health, QIAGEN, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics, Inc., NanoString, NeoGenomics Laboratories and Exact Sciences Corporation (Genomic Health, Inc.).

1. INTRODUCTION

1.1.           REPORT DESCRIPTION

1.2.           WHO SHOULD READ THIS REPORT 

1.3.           KEY MARKET SEGMENTS

1.4.           RESEARCH METHODOLOGY

1.4.1             SECONDARY RESEARCH

1.4.2             DATA ANALYSIS FRAMEWORK

1.4.3             MARKET SIZE ESTIMATION

1.4.4             FORECASTING

1.4.5             PRIMARY RESEARCH AND DATA VALIDATION

2. CANCER/TUMOR PROFILING MARKET – EXECUTIVE SUMMARY

2.1.           MARKET SNAPSHOT, 2022 - 2030, MILLION USD

3. MARKET OVERVIEW

3.1.           MARKET DEFINITION AND SCOPE

3.2.           MARKET DYNAMICS

3.2.1             DRIVERS

3.2.1.1        INCREASING PREVALENCE OF CANCER WORLDWIDE ANTICIPATED TO PROPEL THE MARKET GROWTH

3.2.1.2        RISE IN RESEARCH AND DEVELOPMENT ACTIVITIES AND INCREASING NEW PRODUCT APPROVALS TO BOOST THE MARKET GROWTH

3.2.2             RESTRAINTS

3.2.2.1        HIGH COST OF CANCER PROFILING TESTS TO HAMPER GROWTH OF THE TUMOR PROFILING MARKET

3.2.2.2        POOR REIMBURSEMENT POLICIES AND LACK OF ACCESS TO HEALTHCARE INFRASTRUCTURE REQUIRED FOR CANCER PROFILING ARE LIKELY TO SUPPRESS THE MARKET GROWTH

3.2.3             OPPORTUNITIES

3.2.3.1        HUGE UNMET NEED AND ECONOMIC DEVELOPMENT OF THE DEVELOPING COUNTRIES IN ASIA PACIFIC AND MEA REGION LEVERAGES SIGNIFICANT GROWTH OPPORTUNITIES

4. COVID-19 ANALYSIS

4.1.           IMPACT OF COVID-19 ON CANCER OR TUMOR PROFILING MARKET

5. MARKET SHARE ANALYSIS

5.1.           MARKET SHARE ANALYSIS OF TOP GLOBAL CANCER/TUMOR PROFILING PROVIDERS, 2022

5.2.           MARKET SHARE ANALYSIS OF TOP NORTH AMERICA CANCER/TUMOR PROFILING PROVIDERS, 2022

5.3.           MARKET SHARE ANALYSIS OF TOP EUROPE CANCER/TUMOR PROFILING PROVIDERS, 2022

5.4.           MARKET SHARE ANALYSIS OF TOP APAC CANCER/TUMOR PROFILING PROVIDERS, 2022

5.5.           MARKET SHARE ANALYSIS OF TOP ROW CANCER/TUMOR PROFILING PROVIDERS, 2022

6. PREMIUM INSIGHTS

6.1.           PREVALENCE OF CANCER BY KEY COUNTRIES

6.2.           OVERVIEW OF CGP TECHNOLOGY VS HOTSPOT TECHNOLOGY

6.3.           COMPREHENSIVE GENOME PROFILING:

6.4.           CANCER HOT SPOT TESTING

6.5.           UPTAKE OF CGP VS HOTSPOT TECHNIQUE IN AMEA REGION

6.6.           EXISTING AND EMERGING TECHNOLOGIES OF CANCER/TUMOR PROFILING

6.7.           GENOTYPING

6.8.           NEXT GENERATION SEQUENCING

6.9.           EMERGING TECHNOLOGIES FOR CANCER PROFILING

7. GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

7.1.           OVERVIEW

7.2.           GENOMIC

7.2.1             GENOMIC MARKET, BY REGION

7.2.1.1        NORTH AMERICA GENOMIC MARKET, BY COUNTRY

7.2.1.2        EUROPE GENOMIC MARKET, BY COUNTRY

7.2.1.3        ASIA-PACIFIC GENOMIC MARKET, BY COUNTRY

7.2.1.4        LATIN AMERICA GENOMIC MARKET, BY COUNTRY

7.2.1.5        MIDDLE EAST GENOMIC MARKET, BY COUNTRY

7.2.1.6        AFRICA GENOMIC MARKET, BY COUNTRY

7.3.           PROTEOMIC

7.3.1             PROTEOMIC MARKET, BY REGION

7.3.1.1        NORTH AMERICA PROTEOMIC MARKET, BY COUNTRY

7.3.1.2        EUROPE PROTEOMIC MARKET, BY COUNTRY

7.3.1.3        ASIA-PACIFIC PROTEOMIC MARKET, BY COUNTRY

7.3.1.4        LATIN AMERICA PROTEOMIC MARKET, BY COUNTRY

7.3.1.5        MIDDLE EAST PROTEOMIC MARKET, BY COUNTRY

7.3.1.6        AFRICA PROTEOMIC MARKET, BY COUNTRY

7.4.           METABOLOMICS

7.4.1             METABOLOMICS MARKET, BY REGION

7.4.1.1        NORTH AMERICA METABOLOMICS MARKET, BY COUNTRY

7.4.1.2        EUROPE METABOLOMICS MARKET, BY COUNTRY

7.4.1.3        ASIA-PACIFIC METABOLOMICS MARKET, BY COUNTRY

7.4.1.4        LATIN AMERICA METABOLOMICS MARKET, BY COUNTRY

7.4.1.5        MIDDLE EAST METABOLOMICS MARKET, BY COUNTRY

7.4.1.6        AFRICA METABOLOMICS MARKET, BY COUNTRY

7.5.           EPIGENETICS

7.5.1             EPIGENETICS MARKET, BY REGION

7.5.1.1        NORTH AMERICA EPIGENETICS MARKET, BY COUNTRY

7.5.1.2        EUROPE EPIGENETICS MARKET, BY COUNTRY

7.5.1.3        ASIA-PACIFIC EPIGENETICS MARKET, BY COUNTRY

7.5.1.4        LATIN AMERICA EPIGENETICS MARKET, BY COUNTRY

7.5.1.5        MIDDLE EAST EPIGENETICS MARKET, BY COUNTRY

7.5.1.6        AFRICA EPIGENETICS MARKET, BY COUNTRY

8. GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

8.1.           OVERVIEW

8.2.           IMMUNOASSAY

8.2.1             IMMUNOASSAY MARKET, BY REGION

8.2.1.1        NORTH AMERICA IMMUNOASSAY MARKET, BY COUNTRY

8.2.1.2        EUROPE IMMUNOASSAY MARKET, BY COUNTRY

8.2.1.3        ASIA-PACIFIC IMMUNOASSAY MARKET, BY COUNTRY

8.2.1.4        LATIN AMERICA IMMUNOASSAY MARKET, BY COUNTRY

8.2.1.5        MIDDLE EAST IMMUNOASSAY MARKET, BY COUNTRY

8.2.1.6        AFRICA IMMUNOASSAY MARKET, BY COUNTRY

8.3.           NGS

8.3.1             NGS MARKET, BY REGION

8.3.1.1        NORTH AMERICA NGS MARKET, BY COUNTRY

8.3.1.2        EUROPE NGS MARKET, BY COUNTRY

8.3.1.3        ASIA-PACIFIC NGS MARKET, BY COUNTRY

8.3.1.4        LATIN AMERICA NGS MARKET, BY COUNTRY

8.3.1.5        MIDDLE EAST NGS MARKET, BY COUNTRY

8.3.1.6        AFRICA NGS MARKET, BY COUNTRY

8.4.           INSITU HYBRIDIZATION

8.4.1             GLOBAL INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

8.4.1.1        FISH MARKET, BY REGION

8.4.1.1.1        NORTH AMERICA FISH MARKET, BY COUNTRY

8.4.1.1.2        EUROPE FISH MARKET, BY COUNTRY

8.4.1.1.3        ASIA-PACIFIC FISH MARKET, BY COUNTRY

8.4.1.1.4        LATIN AMERICA FISH MARKET, BY COUNTRY

8.4.1.1.5        MIDDLE EAST FISH MARKET, BY COUNTRY

8.4.1.1.6        AFRICA FISH MARKET, BY COUNTRY

8.4.1.2        CISH MARKET, BY REGION

8.4.1.2.1        NORTH AMERICA CISH MARKET, BY COUNTRY

8.4.1.2.2        EUROPE CISH MARKET, BY COUNTRY

8.4.1.2.3        ASIA-PACIFIC CISH MARKET, BY COUNTRY

8.4.1.2.4        LATIN AMERICA CISH MARKET, BY COUNTRY

8.4.1.2.5        MIDDLE EAST CISH MARKET, BY COUNTRY

8.4.1.2.6        AFRICA CISH MARKET, BY COUNTRY

8.4.2             INSITU HYBRIDIZATION MARKET, BY REGION

8.4.2.1        NORTH AMERICA INSITU HYBRIDIZATION MARKET, BY COUNTRY

8.4.2.2        EUROPE INSITU HYBRIDIZATION MARKET, BY COUNTRY

8.4.2.3        ASIA-PACIFIC INSITU HYBRIDIZATION MARKET, BY COUNTRY

8.4.2.4        LATIN AMERICA INSITU HYBRIDIZATION MARKET, BY COUNTRY

8.4.2.5        MIDDLE EAST INSITU HYBRIDIZATION MARKET, BY COUNTRY

8.4.2.6        AFRICA INSITU HYBRIDIZATION MARKET, BY COUNTRY

8.5.           MASS SPECTROMETRY

8.5.1             MASS SPECTROMETRY MARKET, BY REGION

8.5.1.1        NORTH AMERICA MASS SPECTROMETRY MARKET, BY COUNTRY

8.5.1.2        EUROPE MASS SPECTROMETRY MARKET, BY COUNTRY

8.5.1.3        ASIA-PACIFIC MASS SPECTROMETRY MARKET, BY COUNTRY

8.5.1.4        LATIN AMERICA MASS SPECTROMETRY MARKET, BY COUNTRY

8.5.1.5        MIDDLE EAST MASS SPECTROMETRY MARKET, BY COUNTRY

8.5.1.6        AFRICA MASS SPECTROMETRY MARKET, BY COUNTRY

8.6.           PCR

8.6.1             PCR MARKET, BY REGION

8.6.1.1        NORTH AMERICA PCR MARKET, BY COUNTRY

8.6.1.2        EUROPE PCR MARKET, BY COUNTRY

8.6.1.3        ASIA-PACIFIC PCR MARKET, BY COUNTRY

8.6.1.4        LATIN AMERICA PCR MARKET, BY COUNTRY

8.6.1.5        MIDDLE EAST PCR MARKET, BY COUNTRY

8.6.1.6        AFRICA PCR MARKET, BY COUNTRY

8.7.           MICROARRAY

8.7.1             MICROARRAY MARKET, BY REGION

8.7.1.1        NORTH AMERICA MICROARRAY MARKET, BY COUNTRY

8.7.1.2        EUROPE MICROARRAY MARKET, BY COUNTRY

8.7.1.3        ASIA-PACIFIC MICROARRAY MARKET, BY COUNTRY

8.7.1.4        LATIN AMERICA MICROARRAY MARKET, BY COUNTRY

8.7.1.5        MIDDLE EAST MICROARRAY MARKET, BY COUNTRY

8.7.1.6        AFRICA MICROARRAY MARKET, BY COUNTRY

8.8.           OTHERS

8.8.1             OTHERS MARKET, BY REGION

8.8.1.1        NORTH AMERICA OTHERS MARKET, BY COUNTRY

8.8.1.2        EUROPE OTHERS MARKET, BY COUNTRY

8.8.1.3        ASIA-PACIFIC OTHERS MARKET, BY COUNTRY

8.8.1.4        LATIN AMERICA OTHERS MARKET, BY COUNTRY

8.8.1.5        MIDDLE EAST OTHERS MARKET, BY COUNTRY

8.8.1.6        AFRICA OTHERS MARKET, BY COUNTRY

9. GLOBAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION

9.1.           OVERVIEW

9.2.           RESEARCH APPLICATION

9.2.1             GLOBAL RESEARCH APPLICATION MARKET, BY APPLICATION

9.2.1.1        BIOMARKER DISCOVERY MARKET, BY REGION

9.2.1.1.1        NORTH AMERICA BIOMARKER DISCOVERY MARKET, BY COUNTRY

9.2.1.1.2        EUROPE BIOMARKER DISCOVERY MARKET, BY COUNTRY

9.2.1.1.3        ASIA-PACIFIC BIOMARKER DISCOVERY MARKET, BY COUNTRY

9.2.1.1.4        LATIN AMERICA BIOMARKER DISCOVERY MARKET, BY COUNTRY

9.2.1.1.5        MIDDLE EAST BIOMARKER DISCOVERY MARKET, BY COUNTRY

9.2.1.1.6        AFRICA BIOMARKER DISCOVERY MARKET, BY COUNTRY

9.2.1.2        PERSONALIZED CANCER MEDICINE MARKET, BY REGION

9.2.1.2.1        NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY

9.2.1.2.2        EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY

9.2.1.2.3        ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY

9.2.1.2.4        LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY

9.2.1.2.5        MIDDLE EAST PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY

9.2.1.2.6        AFRICA PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY

9.2.2             RESEARCH APPLICATION MARKET, BY REGION

9.2.2.1        NORTH AMERICA RESEARCH APPLICATION MARKET, BY COUNTRY

9.2.2.2        EUROPE RESEARCH APPLICATION MARKET, BY COUNTRY

9.2.2.3        ASIA-PACIFIC RESEARCH APPLICATION MARKET, BY COUNTRY

9.2.2.4        LATIN AMERICA RESEARCH APPLICATION MARKET, BY COUNTRY

9.2.2.5        MIDDLE EAST RESEARCH APPLICATION MARKET, BY COUNTRY

9.2.2.6        AFRICA RESEARCH APPLICATION MARKET, BY COUNTRY

9.3.           CLINICAL APPLICATION

9.3.1             GLOBAL CLINICAL APPLICATION MARKET, BY APPLICATION

9.3.1.1        ONCOLOGICAL DIAGNOSTICS MARKET, BY REGION

9.3.1.1.1        NORTH AMERICA ONCOLOGICAL DIAGNOSTICS MARKET, BY COUNTRY

9.3.1.1.2        EUROPE ONCOLOGICAL DIAGNOSTICS MARKET, BY COUNTRY

9.3.1.1.3        ASIA-PACIFIC ONCOLOGICAL DIAGNOSTICS MARKET, BY COUNTRY

9.3.1.1.4        LATIN AMERICA ONCOLOGICAL DIAGNOSTICS MARKET, BY COUNTRY

9.3.1.1.5        MIDDLE EAST ONCOLOGICAL DIAGNOSTICS MARKET, BY COUNTRY

9.3.1.1.6        AFRICA ONCOLOGICAL DIAGNOSTICS MARKET, BY COUNTRY

9.3.1.2        PROGNOSTICS MARKET, BY REGION

9.3.1.2.1        NORTH AMERICA PROGNOSTICS MARKET, BY COUNTRY

9.3.1.2.2        EUROPE PROGNOSTICS MARKET, BY COUNTRY

9.3.1.2.3        ASIA-PACIFIC PROGNOSTICS MARKET, BY COUNTRY

9.3.1.2.4        LATIN AMERICA PROGNOSTICS MARKET, BY COUNTRY

9.3.1.2.5        MIDDLE EAST PROGNOSTICS MARKET, BY COUNTRY

9.3.1.2.6        AFRICA PROGNOSTICS MARKET, BY COUNTRY

9.3.1.3        MONITORING AND TREATMENT MARKET, BY REGION

9.3.1.3.1        NORTH AMERICA MONITORING AND TREATMENT MARKET, BY COUNTRY

9.3.1.3.2        EUROPE MONITORING AND TREATMENT MARKET, BY COUNTRY

9.3.1.3.3        ASIA-PACIFIC MONITORING AND TREATMENT MARKET, BY COUNTRY

9.3.1.3.4        LATIN AMERICA MONITORING AND TREATMENT MARKET, BY COUNTRY

9.3.1.3.5        MIDDLE EAST MONITORING AND TREATMENT MARKET, BY COUNTRY

9.3.1.3.6        AFRICA MONITORING AND TREATMENT MARKET, BY COUNTRY

9.3.1.4        SCREENING MARKET, BY REGION

9.3.1.4.1        NORTH AMERICA SCREENING MARKET, BY COUNTRY

9.3.1.4.2        EUROPE SCREENING MARKET, BY COUNTRY

9.3.1.4.3        ASIA-PACIFIC SCREENING MARKET, BY COUNTRY

9.3.1.4.4        LATIN AMERICA SCREENING MARKET, BY COUNTRY

9.3.1.4.5        MIDDLE EAST SCREENING MARKET, BY COUNTRY

9.3.1.4.6        AFRICA SCREENING MARKET, BY COUNTRY

9.3.2             CLINICAL APPLICATION MARKET, BY REGION

9.3.2.1        NORTH AMERICA CLINICAL APPLICATION MARKET, BY COUNTRY

9.3.2.2        EUROPE CLINICAL APPLICATION MARKET, BY COUNTRY

9.3.2.3        ASIA-PACIFIC CLINICAL APPLICATION MARKET, BY COUNTRY

9.3.2.4        LATIN AMERICA CLINICAL APPLICATION MARKET, BY COUNTRY

9.3.2.5        MIDDLE EAST CLINICAL APPLICATION MARKET, BY COUNTRY

9.3.2.6        AFRICA CLINICAL APPLICATION MARKET, BY COUNTRY

10. GLOBAL CANCER/TUMOR PROFILING MARKET, BY REGION

10.1.         OVERVIEW

10.2.         NORTH AMERICA

10.2.1           NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.2.2           NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.2.2.1      NORTH AMERICA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.2.3           NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.2.3.1      NORTH AMERICA RESEARCH APPLICATION MARKET, BY APPLICATION

10.2.3.2      NORTH AMERICA CLINICAL APPLICATION MARKET, BY APPLICATION

10.2.4           NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY

10.2.4.1      U.S.

10.2.4.1.1      U.S. CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.2.4.1.2      U.S. CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.2.4.1.2.1. U.S. INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.2.4.1.3      U.S. CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.2.4.1.3.1. U.S. RESEARCH APPLICATION MARKET, BY APPLICATION

10.2.4.1.3.2. U.S. CLINICAL APPLICATION MARKET, BY APPLICATION

10.2.4.2      CANADA

10.2.4.2.1      CANADA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.2.4.2.2      CANADA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.2.4.2.2.1. CANADA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.2.4.2.3      CANADA CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.2.4.2.3.1. CANADA RESEARCH APPLICATION MARKET, BY APPLICATION

10.2.4.2.3.2. CANADA CLINICAL APPLICATION MARKET, BY APPLICATION

10.3.         EUROPE

10.3.1           EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.3.2           EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.3.2.1      EUROPE INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.3.3           EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.3.3.1      EUROPE RESEARCH APPLICATION MARKET, BY APPLICATION

10.3.3.2      EUROPE CLINICAL APPLICATION MARKET, BY APPLICATION

10.3.4           EUROPE CANCER/TUMOR PROFILING MARKET, BY COUNTRY

10.3.4.1      GERMANY

10.3.4.1.1      GERMANY CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.3.4.1.2      GERMANY CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.3.4.1.2.1. GERMANY INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.3.4.1.3      GERMANY CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.3.4.1.3.1. GERMANY RESEARCH APPLICATION MARKET, BY APPLICATION

10.3.4.1.3.2. GERMANY CLINICAL APPLICATION MARKET, BY APPLICATION

10.3.4.2      FRANCE

10.3.4.2.1      FRANCE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.3.4.2.2      FRANCE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.3.4.2.2.1. FRANCE INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.3.4.2.3      FRANCE CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.3.4.2.3.1. FRANCE RESEARCH APPLICATION MARKET, BY APPLICATION

10.3.4.2.3.2. FRANCE CLINICAL APPLICATION MARKET, BY APPLICATION

10.3.4.3      UK

10.3.4.3.1      UK CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.3.4.3.2      UK CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.3.4.3.2.1. UK INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.3.4.3.3      UK CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.3.4.3.3.1. UK RESEARCH APPLICATION MARKET, BY APPLICATION

10.3.4.3.3.2. UK CLINICAL APPLICATION MARKET, BY APPLICATION

10.3.4.4      SPAIN

10.3.4.4.1      SPAIN CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.3.4.4.2      SPAIN CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.3.4.4.2.1. SPAIN INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.3.4.4.3      SPAIN CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.3.4.4.3.1. SPAIN RESEARCH APPLICATION MARKET, BY APPLICATION

10.3.4.4.3.2. SPAIN CLINICAL APPLICATION MARKET, BY APPLICATION

10.3.4.5      ITALY

10.3.4.5.1      ITALY CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.3.4.5.2      ITALY CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.3.4.5.2.1. ITALY INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.3.4.5.3      ITALY CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.3.4.5.3.1. ITALY RESEARCH APPLICATION MARKET, BY APPLICATION

10.3.4.5.3.2. ITALY CLINICAL APPLICATION MARKET, BY APPLICATION

10.3.4.6      REST OF THE EUROPE

10.3.4.6.1      REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.3.4.6.2      REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.3.4.6.2.1. REST OF THE EUROPE INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.3.4.6.3      REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.3.4.6.3.1. REST OF THE EUROPE RESEARCH APPLICATION MARKET, BY APPLICATION

10.3.4.6.3.2. REST OF THE EUROPE CLINICAL APPLICATION MARKET, BY APPLICATION

10.4.         ASIA-PACIFIC

10.4.1           ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.4.2           ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.4.2.1      ASIA-PACIFIC INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.4.3           ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.4.3.1      ASIA-PACIFIC RESEARCH APPLICATION MARKET, BY APPLICATION

10.4.3.2      ASIA-PACIFIC CLINICAL APPLICATION MARKET, BY APPLICATION

10.4.4           ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY COUNTRY

10.4.4.1      CHINA

10.4.4.1.1      CHINA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.4.4.1.2      CHINA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.4.4.1.2.1. CHINA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.4.4.1.3      CHINA CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.4.4.1.3.1. CHINA RESEARCH APPLICATION MARKET, BY APPLICATION

10.4.4.1.3.2. CHINA CLINICAL APPLICATION MARKET, BY APPLICATION

10.4.4.2      INDIA

10.4.4.2.1      INDIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.4.4.2.2      INDIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.4.4.2.2.1. INDIA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.4.4.2.3      INDIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.4.4.2.3.1. INDIA RESEARCH APPLICATION MARKET, BY APPLICATION

10.4.4.2.3.2. INDIA CLINICAL APPLICATION MARKET, BY APPLICATION

10.4.4.3      JAPAN

10.4.4.3.1      JAPAN CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.4.4.3.2      JAPAN CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.4.4.3.2.1. JAPAN INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.4.4.3.3      JAPAN CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.4.4.3.3.1. JAPAN RESEARCH APPLICATION MARKET, BY APPLICATION

10.4.4.3.3.2. JAPAN CLINICAL APPLICATION MARKET, BY APPLICATION

10.4.4.4      SOUTH KOREA

10.4.4.4.1      SOUTH KOREA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.4.4.4.2      SOUTH KOREA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.4.4.4.2.1. SOUTH KOREA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.4.4.4.3      SOUTH KOREA CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.4.4.4.3.1. SOUTH KOREA RESEARCH APPLICATION MARKET, BY APPLICATION

10.4.4.4.3.2. SOUTH KOREA CLINICAL APPLICATION MARKET, BY APPLICATION

10.4.4.5      SINGAPORE

10.4.4.5.1      SINGAPORE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.4.4.5.2      SINGAPORE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.4.4.5.2.1. SINGAPORE INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.4.4.5.3      SINGAPORE CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.4.4.5.3.1. SINGAPORE RESEARCH APPLICATION MARKET, BY APPLICATION

10.4.4.5.3.2. SINGAPORE CLINICAL APPLICATION MARKET, BY APPLICATION

10.4.4.6      AUSTRALIA

10.4.4.6.1      AUSTRALIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.4.4.6.2      AUSTRALIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.4.4.6.2.1. AUSTRALIA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.4.4.6.3      AUSTRALIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.4.4.6.3.1. AUSTRALIA RESEARCH APPLICATION MARKET, BY APPLICATION

10.4.4.6.3.2. AUSTRALIA CLINICAL APPLICATION MARKET, BY APPLICATION

10.4.4.7      INDONESIA

10.4.4.7.1      INDONESIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.4.4.7.2      INDONESIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.4.4.7.2.1. INDONESIA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.4.4.7.3      INDONESIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.4.4.7.3.1. INDONESIA RESEARCH APPLICATION MARKET, BY APPLICATION

10.4.4.7.3.2. INDONESIA CLINICAL APPLICATION MARKET, BY APPLICATION

10.4.4.8      VIETNAM

10.4.4.8.1      VIETNAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.4.4.8.2      VIETNAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.4.4.8.2.1. VIETNAM INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.4.4.8.3      VIETNAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.4.4.8.3.1. VIETNAM RESEARCH APPLICATION MARKET, BY APPLICATION

10.4.4.8.3.2. VIETNAM CLINICAL APPLICATION MARKET, BY APPLICATION

10.4.4.9      RES OF THE ASIA PACIFIC

10.4.4.9.1      RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.4.4.9.2      RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.4.4.9.2.1. RES OF THE ASIA PACIFIC INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.4.4.9.3      RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.4.4.9.3.1. RES OF THE ASIA PACIFIC RESEARCH APPLICATION MARKET, BY APPLICATION

10.4.4.9.3.2. RES OF THE ASIA PACIFIC CLINICAL APPLICATION MARKET, BY APPLICATION

10.5.         LATIN AMERICA

10.5.1           LATIN AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.5.2           LATIN AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.5.2.1      LATIN AMERICA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.5.3           LATIN AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.5.3.1      LATIN AMERICA RESEARCH APPLICATION MARKET, BY APPLICATION

10.5.3.2      LATIN AMERICA CLINICAL APPLICATION MARKET, BY APPLICATION

10.5.4           LATIN AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY

10.5.4.1      BRAZIL

10.5.4.1.1      BRAZIL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.5.4.1.2      BRAZIL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.5.4.1.2.1. BRAZIL INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.5.4.1.3      BRAZIL CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.5.4.1.3.1. BRAZIL RESEARCH APPLICATION MARKET, BY APPLICATION

10.5.4.1.3.2. BRAZIL CLINICAL APPLICATION MARKET, BY APPLICATION

10.5.4.2      MEXICO

10.5.4.2.1      MEXICO CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.5.4.2.2      MEXICO CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.5.4.2.2.1. MEXICO INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.5.4.2.3      MEXICO CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.5.4.2.3.1. MEXICO RESEARCH APPLICATION MARKET, BY APPLICATION

10.5.4.2.3.2. MEXICO CLINICAL APPLICATION MARKET, BY APPLICATION

10.5.4.3      REST OF LATAM

10.5.4.3.1      REST OF LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.5.4.3.2      REST OF LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.5.4.3.2.1. REST OF LATAM INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.5.4.3.3      REST OF LATAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.5.4.3.3.1. REST OF LATAM RESEARCH APPLICATION MARKET, BY APPLICATION

10.5.4.3.3.2. REST OF LATAM CLINICAL APPLICATION MARKET, BY APPLICATION

10.6.         MIDDLE EAST

10.6.1           MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.6.2           MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.6.2.1      MIDDLE EAST INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.6.3           MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.6.3.1      MIDDLE EAST RESEARCH APPLICATION MARKET, BY APPLICATION

10.6.3.2      MIDDLE EAST CLINICAL APPLICATION MARKET, BY APPLICATION

10.6.4           MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY COUNTRY

10.6.4.1      ISREAL

10.6.4.1.1      ISREAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.6.4.1.2      ISREAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.6.4.1.2.1. ISREAL INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.6.4.1.3      ISREAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.6.4.1.3.1. ISREAL RESEARCH APPLICATION MARKET, BY APPLICATION

10.6.4.1.3.2. ISREAL CLINICAL APPLICATION MARKET, BY APPLICATION

10.6.4.2      UAE

10.6.4.2.1      UAE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.6.4.2.2      UAE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.6.4.2.2.1. UAE INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.6.4.2.3      UAE CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.6.4.2.3.1. UAE RESEARCH APPLICATION MARKET, BY APPLICATION

10.6.4.2.3.2. UAE CLINICAL APPLICATION MARKET, BY APPLICATION

10.6.4.3      SAUDI ARABIA

10.6.4.3.1      SAUDI ARABIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.6.4.3.2      SAUDI ARABIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.6.4.3.2.1. SAUDI ARABIA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.6.4.3.3      SAUDI ARABIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.6.4.3.3.1. SAUDI ARABIA RESEARCH APPLICATION MARKET, BY APPLICATION

10.6.4.3.3.2. SAUDI ARABIA CLINICAL APPLICATION MARKET, BY APPLICATION

10.6.4.4      REST OF THE MIDDLE EAST

10.6.4.4.1      REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.6.4.4.2      REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.6.4.4.2.1. REST OF THE MIDDLE EAST INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.6.4.4.3      REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.6.4.4.3.1. REST OF THE MIDDLE EAST RESEARCH APPLICATION MARKET, BY APPLICATION

10.6.4.4.3.2. REST OF THE MIDDLE EAST CLINICAL APPLICATION MARKET, BY APPLICATION

10.7.         AFRICA

10.7.1           AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.7.2           AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.7.2.1      AFRICA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.7.3           AFRICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.7.3.1      AFRICA RESEARCH APPLICATION MARKET, BY APPLICATION

10.7.3.2      AFRICA CLINICAL APPLICATION MARKET, BY APPLICATION

10.7.4           AFRICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY

10.7.4.1      SOUTH AFRICA

10.7.4.1.1      SOUTH AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.7.4.1.2      SOUTH AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.7.4.1.2.1. SOUTH AFRICA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.7.4.1.3      SOUTH AFRICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.7.4.1.3.1. SOUTH AFRICA RESEARCH APPLICATION MARKET, BY APPLICATION

10.7.4.1.3.2. SOUTH AFRICA CLINICAL APPLICATION MARKET, BY APPLICATION

10.7.4.2      NIGERIA

10.7.4.2.1      NIGERIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.7.4.2.2      NIGERIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.7.4.2.2.1. NIGERIA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.7.4.2.3      NIGERIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.7.4.2.3.1. NIGERIA RESEARCH APPLICATION MARKET, BY APPLICATION

10.7.4.2.3.2. NIGERIA CLINICAL APPLICATION MARKET, BY APPLICATION

10.7.4.3      REST OF AFRICA

10.7.4.3.1      REST OF AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

10.7.4.3.2      REST OF AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

10.7.4.3.2.1. REST OF AFRICA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY

10.7.4.3.3      REST OF AFRICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.7.4.3.3.1. REST OF AFRICA RESEARCH APPLICATION MARKET, BY APPLICATION

10.7.4.3.3.2. REST OF AFRICA CLINICAL APPLICATION MARKET, BY APPLICATION

11. COMPANY PROFILES

11.1.         LUCENCE HEALTH INC

11.1.1           COMPANY OVERVIEW

11.1.2           COMPANY SNAPSHOT

11.1.3           PRODUCT PORTFOLIO

11.1.4           KEY STRATEGIC MOVES & DEVELOPMENTS

11.1.5           SWOT ANALYSIS

11.2.         F. HOFFMANN-LA ROCHE LTD

11.2.1           COMPANY OVERVIEW

11.2.2           COMPANY SNAPSHOT

11.2.3           OPERATING BUSINESS SEGMENTS

11.2.4           PRODUCT PORTFOLIO

11.2.5           BUSINESS PERFORMANCE

11.2.6           SALES BY BUSINESS SEGMENT

11.2.7           SALES BY GEOGRAPHIC SEGMENT

11.2.8           KEY STRATEGIC MOVES & DEVELOPMENTS

11.2.9           SWOT ANALYSIS

11.3.         CARIS LIFE SCIENCES

11.3.1           COMPANY OVERVIEW

11.3.2           COMPANY SNAPSHOT

11.3.3           PRODUCT PORTFOLIO

11.3.4           KEY STRATEGIC MOVES & DEVELOPMENTS

11.3.5           SWOT ANALYSIS

11.4.         ACT GENOMICS CO., LTD

11.4.1           COMPANY OVERVIEW

11.4.2           COMPANY SNAPSHOT

11.4.3           PRODUCT PORTFOLIO

11.4.4           KEY STRATEGIC MOVES & DEVELOPMENTS

11.4.5           SWOT ANALYSIS

11.5.         THERMO FISHER SCIENTIFIC INC.

11.5.1           COMPANY OVERVIEW

11.5.2           COMPANY SNAPSHOT

11.5.3           OPERATING BUSINESS SEGMENTS

11.5.4           PRODUCT PORTFOLIO

11.5.5           BUSINESS PERFORMANCE

11.5.6           SALES BY BUSINESS SEGMENT

11.5.7           SALES BY GEOGRAPHIC SEGMENT

11.5.8           KEY STRATEGIC MOVES & DEVELOPMENTS

11.5.9           SWOT ANALYSIS

11.6.         STRAND LIFE SCIENCES

11.6.1           COMPANY OVERVIEW

11.6.2           COMPANY SNAPSHOT

11.6.3           PRODUCT PORTFOLIO

11.6.4           SWOT ANALYSIS

11.7.         IMB DX, INC.

11.7.1           COMPANY OVERVIEW

11.7.2           COMPANY SNAPSHOT

11.7.3           PRODUCT PORTFOLIO

11.7.4           SWOT ANALYSIS

11.8.         ILLUMINA, INC.

11.8.1           COMPANY OVERVIEW

11.8.2           COMPANY SNAPSHOT

11.8.3           PRODUCT PORTFOLIO

11.8.4           BUSINESS PERFORMANCE

11.8.5           SALES BY GEOGRAPHIC SEGMENT

11.8.6           KEY STRATEGIC MOVES & DEVELOPMENTS

11.8.7           SWOT ANALYSIS

11.9.         GUARDANT HEALTH

11.9.1           COMPANY OVERVIEW

11.9.2           COMPANY SNAPSHOT

11.9.3           PRODUCT PORTFOLIO

11.9.4           BUSINESS PERFORMANCE

11.9.5           SALES BY GEOGRAPHIC SEGMENT

11.9.6           KEY STRATEGIC MOVES & DEVELOPMENTS

11.9.7           SWOT ANALYSIS

11.10.       QIAGEN

11.10.1         COMPANY OVERVIEW

11.10.2         COMPANY SNAPSHOT

11.10.3         PRODUCT PORTFOLIO

11.10.4         BUSINESS PERFORMANCE

11.10.5         SALES BY GEOGRAPHIC SEGMENT

11.10.6         KEY STRATEGIC MOVES & DEVELOPMENTS

11.10.7         SWOT ANALYSIS

11.11.       EXACT SCIENCES CORPORATION (GENOMIC HEALTH, INC.)

11.11.1         COMPANY OVERVIEW

11.11.2         COMPANY SNAPSHOT

11.11.3         PRODUCT PORTFOLIO

11.11.4         BUSINESS PERFORMANCE

11.11.5         SALES BY GEOGRAPHIC SEGMENT

11.11.6         KEY STRATEGIC MOVES & DEVELOPMENTS

11.11.7         SWOT ANALYSIS

11.12.       NEOGENOMICS LABORATORIES

11.12.1         COMPANY OVERVIEW

11.12.2         COMPANY SNAPSHOT

11.12.3         OPERATING BUSINESS SEGMENTS

11.12.4         PRODUCT PORTFOLIO

11.12.5         BUSINESS PERFORMANCE

11.12.6         SALES BY BUSINESS SEGMENT

11.12.7         KEY STRATEGIC MOVES & DEVELOPMENTS

11.12.8         SWOT ANALYSIS

11.13.       NANOSTRING

11.13.1         COMPANY OVERVIEW

11.13.2         COMPANY SNAPSHOT

11.13.3         PRODUCT PORTFOLIO

11.13.4         BUSINESS PERFORMANCE

11.13.5         SALES BY GEOGRAPHIC SEGMENT

11.13.6         KEY STRATEGIC MOVES & DEVELOPMENTS

11.13.7         SWOT ANALYSIS

11.14.       HTG MOLECULAR DIAGNOSTICS, INC.

11.14.1         COMPANY OVERVIEW

11.14.2         COMPANY SNAPSHOT

11.14.3         PRODUCT PORTFOLIO

11.14.4         BUSINESS PERFORMANCE

11.14.5         SWOT ANALYSIS

11.15.       RIBOMED BIOTECHNOLOGIES INC

11.15.1         COMPANY OVERVIEW

11.15.2         COMPANY SNAPSHOT

11.15.3         PRODUCT PORTFOLIO

11.15.4         SWOT ANALYSIS

LIST OF TABLES

TABLE 1. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 2. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 3. GENOMIC MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 4. GENOMIC MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 5. NORTH AMERICA GENOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 6. NORTH AMERICA GENOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 7. EUROPE GENOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 8. EUROPE GENOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 9. ASIA-PACIFIC GENOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 10. ASIA-PACIFIC GENOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 11. LATIN AMERICA GENOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 12. LATIN AMERICA GENOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 13. MIDDLE EAST GENOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 14. MIDDLE EAST GENOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 15. AFRICA GENOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 16. AFRICA GENOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 17. PROTEOMIC MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 18. PROTEOMIC MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 19. NORTH AMERICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 20. NORTH AMERICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 21. EUROPE PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 22. EUROPE PROTEOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 23. ASIA-PACIFIC PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 24. ASIA-PACIFIC PROTEOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 25. LATIN AMERICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 26. LATIN AMERICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 27. MIDDLE EAST PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 28. MIDDLE EAST PROTEOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 29. AFRICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 30. AFRICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 31. METABOLOMICS MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 32. METABOLOMICS MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 33. NORTH AMERICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 34. NORTH AMERICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 35. EUROPE METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 36. EUROPE METABOLOMICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 37. ASIA-PACIFIC METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 38. ASIA-PACIFIC METABOLOMICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 39. LATIN AMERICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 40. LATIN AMERICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 41. MIDDLE EAST METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 42. MIDDLE EAST METABOLOMICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 43. AFRICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 44. AFRICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 45. EPIGENETICS MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 46. EPIGENETICS MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 47. NORTH AMERICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 48. NORTH AMERICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 49. EUROPE EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 50. EUROPE EPIGENETICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 51. ASIA-PACIFIC EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 52. ASIA-PACIFIC EPIGENETICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 53. LATIN AMERICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 54. LATIN AMERICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 55. MIDDLE EAST EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 56. MIDDLE EAST EPIGENETICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 57. AFRICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 58. AFRICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 59. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 60. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 61. IMMUNOASSAY MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 62. IMMUNOASSAY MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 63. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 64. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 65. EUROPE IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 66. EUROPE IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 67. ASIA-PACIFIC IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 68. ASIA-PACIFIC IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 69. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 70. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 71. MIDDLE EAST IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 72. MIDDLE EAST IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 73. AFRICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 74. AFRICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 75. NGS MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 76. NGS MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 77. NORTH AMERICA NGS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 78. NORTH AMERICA NGS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 79. EUROPE NGS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 80. EUROPE NGS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 81. ASIA-PACIFIC NGS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 82. ASIA-PACIFIC NGS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 83. LATIN AMERICA NGS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 84. LATIN AMERICA NGS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 85. MIDDLE EAST NGS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 86. MIDDLE EAST NGS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 87. AFRICA NGS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 88. AFRICA NGS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 89. GLOBAL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 90. GLOBAL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 91. FISH MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 92. FISH MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 93. NORTH AMERICA FISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 94. NORTH AMERICA FISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 95. EUROPE FISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 96. EUROPE FISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 97. ASIA-PACIFIC FISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 98. ASIA-PACIFIC FISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 99. LATIN AMERICA FISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 100. LATIN AMERICA FISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 101. MIDDLE EAST FISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 102. MIDDLE EAST FISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 103. AFRICA FISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 104. AFRICA FISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 105. CISH MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 106. CISH MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 107. NORTH AMERICA CISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 108. NORTH AMERICA CISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 109. EUROPE CISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 110. EUROPE CISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 111. ASIA-PACIFIC CISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 112. ASIA-PACIFIC CISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 113. LATIN AMERICA CISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 114. LATIN AMERICA CISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 115. MIDDLE EAST CISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 116. MIDDLE EAST CISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 117. AFRICA CISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 118. AFRICA CISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 119. INSITU HYBRIDIZATION MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 120. INSITU HYBRIDIZATION MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 121. NORTH AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 122. NORTH AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 123. EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 124. EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 125. ASIA-PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 126. ASIA-PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 127. LATIN AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 128. LATIN AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 129. MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 130. MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 131. AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 132. AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 133. MASS SPECTROMETRY MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 134. MASS SPECTROMETRY MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 135. NORTH AMERICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 136. NORTH AMERICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 137. EUROPE MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 138. EUROPE MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 139. ASIA-PACIFIC MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 140. ASIA-PACIFIC MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 141. LATIN AMERICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 142. LATIN AMERICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 143. MIDDLE EAST MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 144. MIDDLE EAST MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 145. AFRICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 146. AFRICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 147. PCR MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 148. PCR MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 149. NORTH AMERICA PCR MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 150. NORTH AMERICA PCR MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 151. EUROPE PCR MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 152. EUROPE PCR MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 153. ASIA-PACIFIC PCR MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 154. ASIA-PACIFIC PCR MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 155. LATIN AMERICA PCR MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 156. LATIN AMERICA PCR MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 157. MIDDLE EAST PCR MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 158. MIDDLE EAST PCR MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 159. AFRICA PCR MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 160. AFRICA PCR MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 161. MICROARRAY MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 162. MICROARRAY MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 163. NORTH AMERICA MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 164. NORTH AMERICA MICROARRAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 165. EUROPE MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 166. EUROPE MICROARRAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 167. ASIA-PACIFIC MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 168. ASIA-PACIFIC MICROARRAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 169. LATIN AMERICA MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 170. LATIN AMERICA MICROARRAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 171. MIDDLE EAST MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 172. MIDDLE EAST MICROARRAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 173. AFRICA MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 174. AFRICA MICROARRAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 175. OTHERS MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 176. OTHERS MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 177. NORTH AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 178. NORTH AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 179. EUROPE OTHERS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 180. EUROPE OTHERS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 181. ASIA-PACIFIC OTHERS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 182. ASIA-PACIFIC OTHERS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 183. LATIN AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 184. LATIN AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 185. MIDDLE EAST OTHERS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 186. MIDDLE EAST OTHERS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 187. AFRICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 188. AFRICA OTHERS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 189. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 190. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 191. GLOBAL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 192. GLOBAL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 193. BIOMARKER DISCOVERY MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 194. BIOMARKER DISCOVERY MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 195. NORTH AMERICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 196. NORTH AMERICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 197. EUROPE BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 198. EUROPE BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 199. ASIA-PACIFIC BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 200. ASIA-PACIFIC BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 201. LATIN AMERICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 202. LATIN AMERICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 203. MIDDLE EAST BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 204. MIDDLE EAST BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 205. AFRICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 206. AFRICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 207. PERSONALIZED CANCER MEDICINE MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 208. PERSONALIZED CANCER MEDICINE MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 209. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 210. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 211. EUROPE PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 212. EUROPE PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 213. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 214. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 215. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 216. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 217. MIDDLE EAST PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 218. MIDDLE EAST PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 219. AFRICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 220. AFRICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 221. RESEARCH APPLICATION MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 222. RESEARCH APPLICATION MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 223. NORTH AMERICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 224. NORTH AMERICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 225. EUROPE RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 226. EUROPE RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 227. ASIA-PACIFIC RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 228. ASIA-PACIFIC RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 229. LATIN AMERICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 230. LATIN AMERICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 231. MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 232. MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 233. AFRICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 234. AFRICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 235. GLOBAL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 236. GLOBAL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 237. ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 238. ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 239. NORTH AMERICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 240. NORTH AMERICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 241. EUROPE ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 242. EUROPE ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 243. ASIA-PACIFIC ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 244. ASIA-PACIFIC ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 245. LATIN AMERICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 246. LATIN AMERICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 247. MIDDLE EAST ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 248. MIDDLE EAST ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 249. AFRICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 250. AFRICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 251. PROGNOSTICS MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 252. PROGNOSTICS MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 253. NORTH AMERICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 254. NORTH AMERICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 255. EUROPE PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 256. EUROPE PROGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 257. ASIA-PACIFIC PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 258. ASIA-PACIFIC PROGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 259. LATIN AMERICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 260. LATIN AMERICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 261. MIDDLE EAST PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 262. MIDDLE EAST PROGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 263. AFRICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 264. AFRICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 265. MONITORING AND TREATMENT MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 266. MONITORING AND TREATMENT MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 267. NORTH AMERICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 268. NORTH AMERICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 269. EUROPE MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 270. EUROPE MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 271. ASIA-PACIFIC MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 272. ASIA-PACIFIC MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 273. LATIN AMERICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 274. LATIN AMERICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 275. MIDDLE EAST MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 276. MIDDLE EAST MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 277. AFRICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 278. AFRICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 279. SCREENING MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 280. SCREENING MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 281. NORTH AMERICA SCREENING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 282. NORTH AMERICA SCREENING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 283. EUROPE SCREENING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 284. EUROPE SCREENING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 285. ASIA-PACIFIC SCREENING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 286. ASIA-PACIFIC SCREENING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 287. LATIN AMERICA SCREENING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 288. LATIN AMERICA SCREENING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 289. MIDDLE EAST SCREENING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 290. MIDDLE EAST SCREENING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 291. AFRICA SCREENING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 292. AFRICA SCREENING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 293. CLINICAL APPLICATION MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 294. CLINICAL APPLICATION MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 295. NORTH AMERICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 296. NORTH AMERICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 297. EUROPE CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 298. EUROPE CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 299. ASIA-PACIFIC CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 300. ASIA-PACIFIC CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 301. LATIN AMERICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 302. LATIN AMERICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 303. MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 304. MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 305. AFRICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 306. AFRICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 307. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY REGION, 2022-2025, MILLION USD

TABLE 308. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY REGION, 2026-2030, MILLION USD

TABLE 309. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 310. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 311. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 312. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 313. NORTH AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 314. NORTH AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 315. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 316. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 317. NORTH AMERICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 318. NORTH AMERICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 319. NORTH AMERICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 320. NORTH AMERICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 321. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 322. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 323. U.S. CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 324. U.S. CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 325. U.S. CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 326. U.S. CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 327. U.S. INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 328. U.S. INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 329. U.S. CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 330. U.S. CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 331. U.S. RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 332. U.S. RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 333. U.S. CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 334. U.S. CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 335. CANADA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 336. CANADA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 337. CANADA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 338. CANADA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 339. CANADA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 340. CANADA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 341. CANADA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 342. CANADA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 343. CANADA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 344. CANADA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 345. CANADA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 346. CANADA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 347. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 348. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 349. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 350. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 351. EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 352. EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 353. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 354. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 355. EUROPE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 356. EUROPE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 357. EUROPE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 358. EUROPE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 359. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 360. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 361. GERMANY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 362. GERMANY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 363. GERMANY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 364. GERMANY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 365. GERMANY INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 366. GERMANY INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 367. GERMANY CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 368. GERMANY CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 369. GERMANY RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 370. GERMANY RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 371. GERMANY CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 372. GERMANY CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 373. FRANCE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 374. FRANCE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 375. FRANCE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 376. FRANCE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 377. FRANCE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 378. FRANCE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 379. FRANCE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 380. FRANCE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 381. FRANCE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 382. FRANCE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 383. FRANCE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 384. FRANCE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 385. UK CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 386. UK CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 387. UK CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 388. UK CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 389. UK INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 390. UK INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 391. UK CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 392. UK CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 393. UK RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 394. UK RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 395. UK CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 396. UK CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 397. SPAIN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 398. SPAIN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 399. SPAIN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 400. SPAIN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 401. SPAIN INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 402. SPAIN INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 403. SPAIN CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 404. SPAIN CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 405. SPAIN RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 406. SPAIN RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 407. SPAIN CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 408. SPAIN CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 409. ITALY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 410. ITALY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 411. ITALY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 412. ITALY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 413. ITALY INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 414. ITALY INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 415. ITALY CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 416. ITALY CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 417. ITALY RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 418. ITALY RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 419. ITALY CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 420. ITALY CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 421. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 422. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 423. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 424. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 425. REST OF THE EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 426. REST OF THE EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 427. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 428. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 429. REST OF THE EUROPE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 430. REST OF THE EUROPE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 431. REST OF THE EUROPE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 432. REST OF THE EUROPE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 433. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 434. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 435. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 436. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 437. ASIA-PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 438. ASIA-PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 439. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 440. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 441. ASIA-PACIFIC RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 442. ASIA-PACIFIC RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 443. ASIA-PACIFIC CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 444. ASIA-PACIFIC CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 445. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 446. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 447. CHINA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 448. CHINA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 449. CHINA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 450. CHINA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 451. CHINA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 452. CHINA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 453. CHINA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 454. CHINA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 455. CHINA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 456. CHINA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 457. CHINA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 458. CHINA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 459. INDIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 460. INDIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 461. INDIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 462. INDIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 463. INDIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 464. INDIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 465. INDIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 466. INDIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 467. INDIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 468. INDIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 469. INDIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 470. INDIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 471. JAPAN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 472. JAPAN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 473. JAPAN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 474. JAPAN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 475. JAPAN INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 476. JAPAN INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 477. JAPAN CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 478. JAPAN CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 479. JAPAN RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 480. JAPAN RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 481. JAPAN CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 482. JAPAN CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 483. SOUTH KOREA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 484. SOUTH KOREA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 485. SOUTH KOREA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 486. SOUTH KOREA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 487. SOUTH KOREA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 488. SOUTH KOREA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 489. SOUTH KOREA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 490. SOUTH KOREA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 491. SOUTH KOREA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 492. SOUTH KOREA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 493. SOUTH KOREA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 494. SOUTH KOREA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 495. SINGAPORE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 496. SINGAPORE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 497. SINGAPORE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 498. SINGAPORE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 499. SINGAPORE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 500. SINGAPORE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 501. SINGAPORE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 502. SINGAPORE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 503. SINGAPORE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 504. SINGAPORE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 505. SINGAPORE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 506. SINGAPORE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 507. AUSTRALIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 508. AUSTRALIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 509. AUSTRALIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 510. AUSTRALIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 511. AUSTRALIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 512. AUSTRALIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 513. AUSTRALIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 514. AUSTRALIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 515. AUSTRALIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 516. AUSTRALIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 517. AUSTRALIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 518. AUSTRALIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 519. INDONESIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 520. INDONESIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 521. INDONESIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 522. INDONESIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 523. INDONESIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 524. INDONESIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 525. INDONESIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 526. INDONESIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 527. INDONESIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 528. INDONESIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 529. INDONESIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 530. INDONESIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 531. VIETNAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 532. VIETNAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 533. VIETNAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 534. VIETNAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 535. VIETNAM INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 536. VIETNAM INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 537. VIETNAM CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 538. VIETNAM CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 539. VIETNAM RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 540. VIETNAM RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 541. VIETNAM CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 542. VIETNAM CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 543. RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 544. REST OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 545. RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 546. REST OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 547. RES OF THE ASIA PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 548. RES OF THE ASIA PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 549. RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 550. RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 551. RES OF THE ASIA PACIFIC RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 552. RES OF THE ASIA PACIFIC RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 553. RES OF THE ASIA PACIFIC CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 554. RES OF THE ASIA PACIFIC CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 555. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 556. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 557. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 558. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 559. LATIN AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 560. LATIN AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 561. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 562. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 563. LATIN AMERICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 564. LATIN AMERICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 565. LATIN AMERICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 566. LATIN AMERICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 567. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 568. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 569. BRAZIL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 570. BRAZIL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 571. BRAZIL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 572. BRAZIL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 573. BRAZIL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 574. BRAZIL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 575. BRAZIL CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 576. BRAZIL CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 577. BRAZIL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 578. BRAZIL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 579. BRAZIL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 580. BRAZIL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 581. MEXICO CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 582. MEXICO CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 583. MEXICO CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 584. MEXICO CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 585. MEXICO INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 586. MEXICO INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 587. MEXICO CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 588. MEXICO CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 589. MEXICO RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 590. MEXICO RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 591. MEXICO CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 592. MEXICO CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 593. REST OF LATAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 594. REST OF LATAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 595. REST OF LATAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 596. REST OF LATAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 597. REST OF LATAM INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 598. REST OF LATAM INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 599. REST OF LATAM CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 600. REST OF LATAM CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 601. REST OF LATAM RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 602. REST OF LATAM RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 603. REST OF LATAM CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 604. REST OF LATAM CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 605. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 606. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 607. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 608. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 609. MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 610. MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 611. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 612. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 613. MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 614. MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 615. MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 616. MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 617. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 618. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 619. ISREAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 620. ISREAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 621. ISREAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 622. ISREAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 623. ISREAL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 624. ISREAL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 625. ISREAL CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 626. ISREAL CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 627. ISREAL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 628. ISREAL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 629. ISREAL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 630. ISREAL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 631. UAE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 632. UAE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 633. UAE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 634. UAE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 635. UAE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 636. UAE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 637. UAE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 638. UAE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 639. UAE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 640. UAE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 641. UAE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 642. UAE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 643. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 644. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 645. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 646. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 647. SAUDI ARABIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 648. SAUDI ARABIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 649. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 650. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 651. SAUDI ARABIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 652. SAUDI ARABIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 653. SAUDI ARABIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 654. SAUDI ARABIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 655. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 656. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 657. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 658. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 659. REST OF THE MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 660. REST OF THE MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 661. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 662. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 663. REST OF THE MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 664. REST OF THE MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 665. REST OF THE MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 666. REST OF THE MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 667. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 668. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 669. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 670. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 671. AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 672. AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 673. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 674. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 675. AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 676. AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 677. AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 678. AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 679. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD

TABLE 680. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD

TABLE 681. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 682. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 683. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 684. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 685. SOUTH AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 686. SOUTH AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 687. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 688. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 689. SOUTH AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 690. SOUTH AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 691. SOUTH AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 692. SOUTH AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 693. NIGERIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 694. NIGERIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 695. NIGERIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 696. NIGERIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 697. NIGERIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 698. NIGERIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 699. NIGERIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 700. NIGERIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 701. NIGERIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 702. NIGERIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 703. NIGERIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 704. NIGERIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 705. REST OF AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD

TABLE 706. REST OF AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD

TABLE 707. REST OF AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 708. REST OF AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 709. REST OF AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD

TABLE 710. REST OF AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD

TABLE 711. REST OF AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 712. REST OF AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 713. REST OF AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 714. REST OF AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 715. REST OF AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD

TABLE 716. REST OF AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD

TABLE 717. LUCENCE HEALTH INC: COMPANY SNAPSHOT

TABLE 718. LUCENCE HEALTH INC: PRODUCT PORTFOLIO

TABLE 719. LUCENCE HEALTH INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 720. F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT

TABLE 721. F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS

TABLE 722. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO

TABLE 723. F. HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 724. CARIS LIFE SCIENCES: COMPANY SNAPSHOT

TABLE 725. CARIS LIFE SCIENCES: PRODUCT PORTFOLIO

TABLE 726. CARIS LIFE SCIENCES: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 727. ACT GENOMICS CO., LTD: COMPANY SNAPSHOT

TABLE 728. ACT GENOMICS CO., LTD: PRODUCT PORTFOLIO

TABLE 729. ACT GENOMICS CO., LTD: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 730. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

TABLE 731. THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS

TABLE 732. THERMO FISHER SCIENTIFIC INC: PRODUCT PORTFOLIO

TABLE 733. THERMO FISHER SCIENTIFIC INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 734. STRAND LIFE SCIENCES: COMPANY SNAPSHOT

TABLE 735. STRAND LIFE SCIENCES: PRODUCT PORTFOLIO

TABLE 736. IMB DX, INC.: COMPANY SNAPSHOT

TABLE 737. IMB DX, INC.: PRODUCT PORTFOLIO

TABLE 738. ILLUMINA, INC.: COMPANY SNAPSHOT

TABLE 739. ILLUMINA, INC.: PRODUCT PORTFOLIO

TABLE 740. ILLUMINA, INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 741. GUARDANT HEALTH: COMPANY SNAPSHOT

TABLE 742. GUARDANT HEALTH: PRODUCT PORTFOLIO

TABLE 743. GUARDANT HEALTH: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 744. QIAGEN: COMPANY SNAPSHOT

TABLE 745. QIAGEN: PRODUCT PORTFOLIO

TABLE 746. QIAGEN: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 747. EXACT SCIENCES CORPORATION (GENOMIC HEALTH, INC.): COMPANY SNAPSHOT

TABLE 748. EXACT SCIENCES CORPORATION (GENOMIC HEALTH, INC.): PRODUCT PORTFOLIO

TABLE 749. EXACT SCIENCES CORPORATION (GENOMIC HEALTH, INC.): KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 750. NEOGENOMICS LABORATORIES: COMPANY SNAPSHOT

TABLE 751. NEOGENOMICS LABORATORIES: OPERATING SEGMENTS

TABLE 752. NEOGENOMICS LABORATORIES: PRODUCT PORTFOLIO

TABLE 753. NEOGENOMICS LABORATORIES: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 754. NANOSTRING: COMPANY SNAPSHOT

TABLE 755. NANOSTRING: PRODUCT PORTFOLIO

TABLE 756. NANOSTRING: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 757. HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY SNAPSHOT

TABLE 758. HTG MOLECULAR DIAGNOSTICS, INC.: PRODUCT PORTFOLIO

TABLE 759. RIBOMED BIOTECHNOLOGIES INC: COMPANY SNAPSHOT

TABLE 760. RIBOMED BIOTECHNOLOGIES INC: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. MARKET SHARE ANALYSIS OF TOP GLOBAL CANCER/TUMOR PROFILING PROVIDERS, 2022

FIGURE 2. MARKET SHARE ANALYSIS OF TOP NORTH AMERICA CANCER/TUMOR PROFILING PROVIDERS, 2022

FIGURE 3. MARKET SHARE ANALYSIS OF TOP EUROPE CANCER/TUMOR PROFILING PROVIDERS, 2022

FIGURE 4. MARKET SHARE ANALYSIS OF TOP APAC CANCER/TUMOR PROFILING PROVIDERS, 2022

FIGURE 5. MARKET SHARE ANALYSIS OF TOP ROW CANCER/TUMOR PROFILING PROVIDERS, 2022

FIGURE 6. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 7. GENOMIC MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 8. NORTH AMERICA GENOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 9. EUROPE GENOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 10. ASIA-PACIFIC GENOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 11. LATIN AMERICA GENOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 12. MIDDLE EAST GENOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 13. AFRICA GENOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 14. PROTEOMIC MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 15. NORTH AMERICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 16. EUROPE PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 17. ASIA-PACIFIC PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 18. LATIN AMERICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 19. MIDDLE EAST PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 20. AFRICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 21. METABOLOMICS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 22. NORTH AMERICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 23. EUROPE METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 24. ASIA-PACIFIC METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 25. LATIN AMERICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 26. MIDDLE EAST METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 27. AFRICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 28. EPIGENETICS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 29. NORTH AMERICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 30. EUROPE EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 31. ASIA-PACIFIC EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 32. LATIN AMERICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 33. MIDDLE EAST EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 34. AFRICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 35. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 36. IMMUNOASSAY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 37. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 38. EUROPE IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 39. ASIA-PACIFIC IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 40. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 41. MIDDLE EAST IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 42. AFRICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 43. NGS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 44. NORTH AMERICA NGS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 45. EUROPE NGS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 46. ASIA-PACIFIC NGS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 47. LATIN AMERICA NGS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 48. MIDDLE EAST NGS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 49. AFRICA NGS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 50. GLOBAL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 51. FISH MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 52. NORTH AMERICA FISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 53. EUROPE FISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 54. ASIA-PACIFIC FISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 55. LATIN AMERICA FISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 56. MIDDLE EAST FISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 57. AFRICA FISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 58. CISH MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 59. NORTH AMERICA CISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 60. EUROPE CISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 61. ASIA-PACIFIC CISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 62. LATIN AMERICA CISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 63. MIDDLE EAST CISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 64. AFRICA CISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 65. INSITU HYBRIDIZATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 66. NORTH AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 67. EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 68. ASIA-PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 69. LATIN AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 70. MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 71. AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 72. MASS SPECTROMETRY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 73. NORTH AMERICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 74. EUROPE MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 75. ASIA-PACIFIC MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 76. LATIN AMERICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 77. MIDDLE EAST MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 78. AFRICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 79. PCR MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 80. NORTH AMERICA PCR MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 81. EUROPE PCR MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 82. ASIA-PACIFIC PCR MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 83. LATIN AMERICA PCR MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 84. MIDDLE EAST PCR MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 85. AFRICA PCR MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 86. MICROARRAY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 87. NORTH AMERICA MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 88. EUROPE MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 89. ASIA-PACIFIC MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 90. LATIN AMERICA MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 91. MIDDLE EAST MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 92. AFRICA MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 93. OTHERS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 94. NORTH AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 95. EUROPE OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 96. ASIA-PACIFIC OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 97. LATIN AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 98. MIDDLE EAST OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 99. AFRICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 100. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 101. GLOBAL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 102. BIOMARKER DISCOVERY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 103. NORTH AMERICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 104. EUROPE BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 105. ASIA-PACIFIC BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 106. LATIN AMERICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 107. MIDDLE EAST BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 108. AFRICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 109. PERSONALIZED CANCER MEDICINE MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 110. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 111. EUROPE PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 112. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 113. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 114. MIDDLE EAST PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 115. AFRICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 116. RESEARCH APPLICATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 117. NORTH AMERICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 118. EUROPE RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 119. ASIA-PACIFIC RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 120. LATIN AMERICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 121. MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 122. AFRICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 123. GLOBAL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 124. ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 125. NORTH AMERICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 126. EUROPE ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 127. ASIA-PACIFIC ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 128. LATIN AMERICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 129. MIDDLE EAST ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 130. AFRICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 131. PROGNOSTICS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 132. NORTH AMERICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 133. EUROPE PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 134. ASIA-PACIFIC PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 135. LATIN AMERICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 136. MIDDLE EAST PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 137. AFRICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 138. MONITORING AND TREATMENT MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 139. NORTH AMERICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 140. EUROPE MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 141. ASIA-PACIFIC MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 142. LATIN AMERICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 143. MIDDLE EAST MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 144. AFRICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 145. SCREENING MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 146. NORTH AMERICA SCREENING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 147. EUROPE SCREENING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 148. ASIA-PACIFIC SCREENING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 149. LATIN AMERICA SCREENING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 150. MIDDLE EAST SCREENING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 151. AFRICA SCREENING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 152. CLINICAL APPLICATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 153. NORTH AMERICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 154. EUROPE CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 155. ASIA-PACIFIC CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 156. LATIN AMERICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 157. MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 158. AFRICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 159. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 160. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 161. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 162. NORTH AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 163. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 164. NORTH AMERICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 165. NORTH AMERICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 166. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 167. U.S. CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 168. U.S. CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 169. U.S. INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 170. U.S. CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 171. U.S. RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 172. U.S. CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 173. CANADA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 174. CANADA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 175. CANADA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 176. CANADA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 177. CANADA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 178. CANADA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 179. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 180. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 181. EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 182. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 183. EUROPE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 184. EUROPE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 185. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 186. GERMANY CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 187. GERMANY CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 188. GERMANY INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 189. GERMANY CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 190. GERMANY RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 191. GERMANY CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 192. FRANCE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 193. FRANCE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 194. FRANCE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 195. FRANCE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 196. FRANCE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 197. FRANCE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 198. UK CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 199. UK CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 200. UK INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 201. UK CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 202. UK RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 203. UK CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 204. SPAIN CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 205. SPAIN CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 206. SPAIN INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 207. SPAIN CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 208. SPAIN RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 209. SPAIN CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 210. ITALY CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 211. ITALY CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 212. ITALY INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 213. ITALY CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 214. ITALY RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 215. ITALY CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 216. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 217. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 218. REST OF THE EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 219. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 220. REST OF THE EUROPE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 221. REST OF THE EUROPE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 222. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 223. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 224. ASIA-PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 225. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 226. ASIA-PACIFIC RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 227. ASIA-PACIFIC CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 228. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 229. CHINA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 230. CHINA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 231. CHINA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 232. CHINA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 233. CHINA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 234. CHINA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 235. INDIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 236. INDIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 237. INDIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 238. INDIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 239. INDIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 240. INDIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 241. JAPAN CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 242. JAPAN CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 243. JAPAN INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 244. JAPAN CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 245. JAPAN RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 246. JAPAN CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 247. SOUTH KOREA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 248. SOUTH KOREA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 249. SOUTH KOREA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 250. SOUTH KOREA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 251. SOUTH KOREA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 252. SOUTH KOREA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 253. SINGAPORE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 254. SINGAPORE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 255. SINGAPORE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 256. SINGAPORE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 257. SINGAPORE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 258. SINGAPORE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 259. AUSTRALIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 260. AUSTRALIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 261. AUSTRALIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 262. AUSTRALIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 263. AUSTRALIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 264. AUSTRALIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 265. INDONESIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 266. INDONESIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 267. INDONESIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 268. INDONESIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 269. INDONESIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 270. INDONESIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 271. VIETNAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 272. VIETNAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 273. VIETNAM INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 274. VIETNAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 275. VIETNAM RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 276. VIETNAM CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 277. RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 278. RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 279. RES OF THE ASIA PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 280. RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 281. RES OF THE ASIA PACIFIC RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 282. RES OF THE ASIA PACIFIC CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 283. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 284. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 285. LATIN AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 286. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 287. LATIN AMERICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 288. LATIN AMERICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 289. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 290. BRAZIL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 291. BRAZIL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 292. BRAZIL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 293. BRAZIL CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 294. BRAZIL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 295. BRAZIL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 296. MEXICO CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 297. MEXICO CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 298. MEXICO INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 299. MEXICO CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 300. MEXICO RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 301. MEXICO CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 302. REST OF LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 303. REST OF LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 304. REST OF LATAM INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 305. REST OF LATAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 306. REST OF LATAM RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 307. REST OF LATAM CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 308. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 309. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 310. MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 311. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 312. MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 313. MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 314. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 315. ISREAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 316. ISREAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 317. ISREAL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 318. ISREAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 319. ISREAL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 320. ISREAL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 321. UAE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 322. UAE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 323. UAE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 324. UAE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 325. UAE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 326. UAE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 327. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 328. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 329. SAUDI ARABIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 330. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 331. SAUDI ARABIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 332. SAUDI ARABIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 333. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 334. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 335. REST OF THE MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 336. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 337. REST OF THE MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 338. REST OF THE MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 339. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 340. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 341. AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 342. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 343. AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 344. AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 345. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 346. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 347. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 348. SOUTH AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 349. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 350. SOUTH AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 351. SOUTH AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 352. NIGERIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 353. NIGERIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 354. NIGERIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 355. NIGERIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 356. NIGERIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 357. NIGERIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 358. REST OF AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 359. REST OF AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 360. REST OF AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 361. REST OF AFRICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 362. REST OF AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 363. REST OF AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD

FIGURE 364. LUCENCE HEALTH INC: SWOT ANALYSIS

FIGURE 365. F. HOFFMANN-LA ROCHE LTD: NET SALES, 2018–2022 ($MILLION)

FIGURE 366. F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS

FIGURE 367. CARIS LIFE SCIENCES.: SWOT ANALYSIS

FIGURE 368. ACT GENOMICS CO., LTD.: SWOT ANALYSIS

FIGURE 369. THERMO FISHER SCIENTIFIC INC: NET SALES, 2018–2022 ($MILLION)

FIGURE 370. THERMO FISHER SCIENTIFIC INC: SWOT ANALYSIS

FIGURE 371. STRAND LIFE SCIENCES: SWOT ANALYSIS

FIGURE 372. IMB DX, INC.: SWOT ANALYSIS

FIGURE 373. ILLUMINA, INC.: NET SALES, 2018–2022 ($MILLION)

FIGURE 374. ILLUMINA, INC: SWOT ANALYSIS

FIGURE 375. GUARDANT HEALTH: NET SALES, 2018–2022 ($MILLION)

FIGURE 376. GUARDANT HEALTH: SWOT ANALYSIS

FIGURE 377. QIAGEN: NET SALES, 2018–2022 ($MILLION)

FIGURE 378. QIAGEN: SWOT ANALYSIS

FIGURE 379. EXACT SCIENCES CORPORATION (GENOMIC HEALTH, INC.): NET SALES, 2018–2022 ($MILLION)

FIGURE 380. EXACT SCIENCES CORPORATION (GENOMIC HEALTH, INC.): SWOT ANALYSIS

FIGURE 381. NEOGENOMICS LABORATORIES: NET SALES, 2018–2022 ($MILLION)

FIGURE 382. NEOGENOMICS LABORATORIES: SWOT ANALYSIS

FIGURE 383. NANOSTRING: NET SALES, 2018–2022 ($MILLION)

FIGURE 384. NANOSTRING: SWOT ANALYSIS

FIGURE 385. HTG MOLECULAR DIAGNOSTICS, INC.: NET SALES, 2018–2022 ($MILLION)

FIGURE 386. HTG MOLECULAR DIAGNOSTICS, INC.: SWOT ANALYSIS

FIGURE 387. RIBOMED BIOTECHNOLOGIES INC: SWOT ANALYSIS

KEY PLAYERS

  • Lucence Health Inc.
  • F. Hoffmann-La Roche Ltd
  • Caris Life Sciences
  • ACT Genomics Co., LTD
  • Thermo Fisher Scientific Inc.
  • Strand Life Sciences
  • IMB Dx, Inc.
  • Illumina, Inc.
  • Guardant Health
  • QIAGEN
  • Ribomed Biotechnologies Inc.
  • HTG Molecular Diagnostics, Inc.
  • NanoString
  • NeoGenomics Laboratories
  • Exact Sciences Corporation (Genomic Health, Inc.)

Frequently Asked Questions
What will be the worth of global Cancer Tumor Profiling market by the end of 2030?

According to the report published by Next Move Strategy Consulting, the Cancer Tumor Profiling market business is expected to hit at $31.67 billion (USD) by 2030.

Which region is expected to hold the highest market share in the Cancer Tumor Profiling Market?

North America is expected to hold the highest market share in the global market. The region is expected to witness remarkable growth as it houses the major key players in the market.

Which are the top companies in the Cancer Tumor Profiling industry?

Lucence Health Inc., F. Hoffmann-La Roche Ltd, Caris Life Sciences, ACT Genomics Co., LTD, Thermo Fisher Scientific Inc., Strand Life Sciences, IMB Dx, Inc., Illumina, Inc., Guardant Health, QIAGEN, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics, Inc., NanoString, NeoGenomics Laboratories and Exact Sciences Corporation (Genomic Health, Inc.).

What are the market segmentations and scope of the study?

The global Cancer Tumor Profiling market share analysis is based on technique, technology, application and geography.

How big is the Cancer Tumor Profiling market?

Currently (in 2020), the market value stands at USD 9.32 billion and it is anticipated to reach USD 31.67 billion by 2030.